Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.66)
# 718
Out of 5,182 analysts
124
Total ratings
55.08%
Success rate
23.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.25 | +179.57% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $5.82 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $33.43 | +49.57% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $13.07 | -4.36% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $79.01 | +18.97% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $9.59 | +108.55% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $195.93 | +10.75% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $5.92 | +35.14% | 11 | Mar 7, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $71.89 | +1.54% | 9 | Feb 26, 2025 | |
| GRCE Grace Therapeutics | Reiterates: Buy | $12 | $3.57 | +236.13% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $2.61 | +187.36% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.00 | +703.21% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $2.13 | +2,693.43% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $0.61 | +32,359.02% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.25
Upside: +179.57%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $5.82
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $33.43
Upside: +49.57%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $13.07
Upside: -4.36%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $79.01
Upside: +18.97%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $9.59
Upside: +108.55%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $195.93
Upside: +10.75%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $5.92
Upside: +35.14%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $71.89
Upside: +1.54%
Grace Therapeutics
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.57
Upside: +236.13%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $2.61
Upside: +187.36%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.00
Upside: +703.21%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $2.13
Upside: +2,693.43%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $0.61
Upside: +32,359.02%